Interferons (IFNs) mediate cellular defence against viral pathogens by upregulation of IFN-stimulated genes whose products interact with viral components or alter cellular physiology to suppress viral replication [1] [2] [3] . Among the IFNstimulated genes that can inhibit influenza A virus (IAV) 4 are the myxovirus resistance 1 GTPase 5 and IFN-induced transmembrane protein 3 (refs 6,7 ). Here, we use ectopic expression and gene knockout to demonstrate that the IFN-inducible 219-amino acid short isoform of human nuclear receptor coactivator 7 (NCOA7) is an inhibitor of IAV as well as other viruses that enter the cell by endocytosis, including hepatitis C virus. NCOA7 interacts with the vacuolar H + -ATPase (V-ATPase) and its expression promotes cytoplasmic vesicle acidification, lysosomal protease activity and the degradation of endocytosed antigen.
Interferons (IFNs) mediate cellular defence against viral pathogens by upregulation of IFN-stimulated genes whose products interact with viral components or alter cellular physiology to suppress viral replication [1] [2] [3] . Among the IFNstimulated genes that can inhibit influenza A virus (IAV) 4 are the myxovirus resistance 1 GTPase 5 and IFN-induced transmembrane protein 3 (refs 6, 7 ). Here, we use ectopic expression and gene knockout to demonstrate that the IFN-inducible 219-amino acid short isoform of human nuclear receptor coactivator 7 (NCOA7) is an inhibitor of IAV as well as other viruses that enter the cell by endocytosis, including hepatitis C virus. NCOA7 interacts with the vacuolar H + -ATPase (V-ATPase) and its expression promotes cytoplasmic vesicle acidification, lysosomal protease activity and the degradation of endocytosed antigen.
Step-wise dissection of the IAV entry pathway demonstrates that NCOA7 inhibits fusion of the viral and endosomal membranes and subsequent nuclear translocation of viral ribonucleoproteins. Therefore, NCOA7 provides a mechanism for immune regulation of endolysosomal physiology that not only suppresses viral entry into the cytosol from this compartment but may also regulate other V-ATPaseassociated cellular processes, such as physiological adjustments to nutritional status, or the maturation and function of antigen-presenting cells.
Previously, we characterized a panel of primary and immortalized cells for interferon α (IFNα )-inducible resistance to human immunodeficiency virus type-1 (HIV-1) infection as the basis for the transcriptomic-led identification of IFN-stimulated genes (ISGs) that suppress virus infection 8, 9 . Among the complementary DNAs (cDNAs) of interest, the IFN-inducible short isoform (isoform 4) of human nuclear receptor coactivator 7 (NCOA7)-also termed NCOA7-alternative start 10 -was cloned into pEasiLV-MCS-a doxycycline-inducible, E2-crimson-expressing lentiviral vector 9 -and evaluated for anti-retroviral activity. HIV-1 susceptible U87MG CD4 + CXCR4 + cultures were transduced with NCOA7-expressing EasiLV or a negative control vector. Cells were challenged with a vesicular stomatitis virus G-glycoprotein (VSV-G)-pseudotyped HIV-1-derived lentiviral vector that expresses green fluorescent protein (GFP) 11 . At 48 h, E2-crimson-positive cells were gated and the percentage of infected cells was enumerated by flow cytometry. At multiple viral doses, NCOA7 expression decreased virus infectivity (Fig. 1a) , with similar effects seen with VSV-G-pseudotyped vectors derived from diverse retroviruses, including simian immunodeficiency virus, equine infectious anaemia virus and feline immunodeficiency virus ( Supplementary Fig. 1a ). In contrast, in challenges with HIV-1/Nefinternal ribosome entry signal (IRES)-GFP carrying its natural envelope glycoprotein (Env), NCOA7 displayed no discernible antiviral activity (Fig. 1a) . We surmised that the differences in NCOA7 sensitivity between HIV-1 particles carrying HIV-1 Env or VSV-G could be dictated by the viral entry pathway: HIV-1 is believed to mediate pH-independent membrane fusion 12 , whereas VSV-G undergoes pH-dependent fusion in early endosomes 13 . We therefore extended this pseudotyping analysis to additional viral envelope glycoproteins; the rabies virus glycoprotein (RABV-G) mediates entry via endosomes, whereas Env of amphotropic murine leukaemia virus (MLV) and the feline endogenous retrovirus RD114 are thought to facilitate pH-independent membrane fusion. NCOA7 inhibited infection by pseudotypes carrying RABV-G but not amphotropic MLV or RD114 Env (Fig. 1b) , consistent with suppressed entry from the endocytic pathway.
Next, we tested the effect of NCOA7 on two replication-competent viruses from diverse families that naturally enter by endocytic uptake-namely, influenza A virus (IAV; an orthomyxovirus) and hepatitis C virus (HCV; a flavivirus). A549 cells transduced with a constitutively expressing NCOA7 lentiviral vector, or control cells, were challenged with IAV, fixed at 5 h and stained with an antibody specific for viral nucleoprotein-a viral protein that accumulates to high levels in the nucleus during productive viral replication following de novo expression. NCOA7 expression reduced the number of cells with nuclear nucleoprotein staining by around sixfold (Fig. 1c,d) ; similarly, an engineered IAV expressing NanoLuc luciferase was also inhibited across a range of viral doses ( Supplementary Fig. 1b) . The suppressive effects of NCOA7 were most evident at earlier time points, as illustrated by IAV infection of control versus NCOA7-expressing 293T cultures and time-lapse microscopy (Supplementary Video 1). For HCV infection, Huh-7.5 cell cultures were stably transduced with an NCOA7-expressing (or control) lentiviral vector, challenged with HCV, and harvested and stained with an anti-NS5A antibody at 48 h: NCOA7 expression resulted in a decrease in HCV infection of ~50% (Fig. 1e) .
Having demonstrated that the provision of NCOA7 was sufficient to inhibit IAV infection, we complemented this approach by assessing the contribution of endogenous NCOA7 to the IFNα -induced suppression of IAV infection. We used clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPRassociated protein 9 (Cas9)-mediated genome editing and guide RNAs targeting the unique region of the short isoform to
The interferon-inducible isoform of NCOA7 inhibits endosome-mediated viral entry Letters NATure MICrObIOlOGy generate A549 cell populations (Fig. 1f,g and Supplementary  Fig. 2a ) and clones ( Supplementary Fig. 2b -e) lacking this isoform. All cultures in which the short isoform had been inactivated displayed diminished IFNα -induced suppression of IAV relative to control cells. We additionally created matching cell populations in which the integral membrane protein IFN-induced transmembrane protein 3 (IFITM3; ref. 6 ) was knocked out alone or in combination with NCOA7 (Fig. 1f,g ). Reductions in IFNα -mediated inhibition were seen in cells that expressed or lacked NCOA7 in the context of IFITM3 knockout (around sixfold inhibition in single IFITM3 knockout versus 2.7-fold inhibition in IFITM3/NCOA7 double knockout), indicating that the antiviral effects of NCOA7 and IFITM3 are cumulative as well as independent.
To further verify that NCOA7 and IFITM3 inhibit IAV independent of each other, we showed (using knockout clonal lines) that NCOA7-mediated inhibition of infection is unaffected by IFITM3 knockout and vice versa ( Supplementary Fig. 3a-c) . Reintroduction of codon-optimized NCOA7 isoform 4, which cannot be targeted by our guide RNAs, into NCOA7 knockout cell lines reconstituted the full IFNα -mediated inhibition of IAV ( Supplementary Fig. 3d ). Together, these findings confirm that NCOA7 is a significant component of IFNα -induced protection against IAV infection.
Next, we employed a series of sequential imaging flow cytometry-based assays to dissect the step(s) in IAV infection inhibited by NCOA7 (Fig. 2a) 14, 15 . First, using A549 cells expressing NCOA7 or a negative control (CD8), we quantified low pH-induced conformational changes in haemagglutinin at 1 h post-infection using monoclonal antibody A1, which specifically recognizes acidified haemagglutinin 14, 16 . Haemagglutinin acidification was not compromised in the presence of NCOA7 (Fig. 2b) . Second, to study viral membrane fusion, we labelled IAV particles with the self-quenching dye SP-DiOC18. Fluorescence dequenching of SP-DiOC18 occurs on viral-endosome membrane fusion (reported to occur at pH < 5 for A/Victoria/3/75 and ~pH 5.5 for A/Eng/195/2009; refs 17, 18 ), and . e, As in c, but cells were incubated in serum-free media containing 250 μ g ml −1 of DQ-Ova or Ova-647 for 1 h followed by washing. Ova-647-containing cells were subsequently fixed, whereas DQ-Ova-containing samples were incubated for a further 4 h before washing and fixation. DQ-Ova fluorescence was enumerated by flow cytometry and Ova-647 was used to normalize for uptake. The mean of three independent experiments is shown, with error bars representing one s.d. from the mean.
Letters
NATure MICrObIOlOGy cells with CCF2-AM dye, cleavage was analysed by flow cytometry, showing that cytosolic entry was consistently reduced in NCOA7-expressing cells ( Supplementary Fig. 4a,b) . Third, to examine the nuclear import of incoming viral ribonucleoproteins (vRNPs), we infected A549 cells with IAV at a high multiplicity of infection (MOI) in the presence of cycloheximide (to prevent de novo protein synthesis), and quantified nuclear nucleoprotein staining at 5 h. Consistent with the fusion assays, NCOA7 expression resulted in a decrease of ~60% in the number of cells exhibiting a high level of nucleoprotein import (defined by the control upper quintile) (Fig. 2d) . Supplementary Fig. 4c confirms this result by confocal microscopy. In summary, our mapping strategy indicated that NCOA7 inhibits viral membrane fusion, whereas neither haemagglutinin acidification nor viral uptake into the endocytic pathway ( Supplementary Fig. 4d ) was compromised.
NCOA7 was first identified as an oestrogen receptor-associated protein that localizes to the nucleus on oestradiol treatment 19, 20 . It is thought to have arisen from gene duplication of its homologue, OXR1, with which it shares oxidation resistance properties 20 . The short isoform of NCOA7, studied herein, has a unique amino-terminal region of 25 amino acids and otherwise contains the carboxyterminal five exons of the longest isoform 10 . The carboxy-terminal region of OXR/NCOA7 comprises a TLDc (TBC/LysM domaincontaining) domain, the function of which is currently not understood 20 . In contrast with the longer isoforms, the short isoform displays cytoplasmic staining on stable expression (Supplementary Fig. 5a ) with no observable co-localization or accumulation with markers of early/late endosomes ( Supplementary Fig. 5a ), and is the only isoform that is IFN inducible (and lipopolysaccharide inducible) 10 -a property presumably conferred by the canonical IFN-sensitive response element sequence located upstream of its unique amino-terminal exon ( Supplementary Fig. 5b ) 10 . Previous proteomic analyses of the V-ATPase have reported interactions between the ATP6V1B1 subunit (a component of the catalytic motor) and both NCOA7 and OXR1 (refs 21, 22 ), consistent with activity as potential V-ATPase regulators 23 . ATP6V1B1 is the B-subunit that is expressed primarily in kidney cells and cells of the inner ear, whereas ATP6V1B2 is expressed in non-renal tissues. Because NCOA7 disrupts endosome-mediated virus entry, we used co-immunoprecipitation to assess whether NCOA7 associates with ATP6V1B2. Flag-tagged NCOA7 (or E2-crimson) was expressed in U87MG cells, and whole cell lysates subjected to antiFlag immunoprecipitation, followed by immunoblot analysis using an ATP6V1B2-specific antibody. As shown in Fig. 3a , interactions between the short isoform of NCOA7 and ATP6V1B2, as well as multiple other subunits of V-ATPase, were readily detected.
Next, we used cell-based assays of V-ATPase function to seek evidence of NCOA7-mediated upregulation. The effect of NCOA7 on cytoplasmic vesicle acidification was examined using LysoSensor Green DND-189 dye, the fluorescence dequenching of which is pH dependent (pKa 5.2). Living cells were treated for 1 h before visualization, with NCOA7 expression markedly increasing the number of LysoSensor Green-positive punctae (Fig. 3c) , as well as the fluorescence intensity in individual vesicles (Fig. 3b) . Ratiometric pH analysis using LysoSensor Yellow/Blue demonstrated that this was at least partly due to true decreases in vesicular pH (Fig. 3c ). These observations are consistent with NCOA7 promoting increased vesicular acidification through a regulatory interaction with V-ATPase.
The regulation of V-ATPase has been well described in the context of lipopolysaccharide-induced maturation of dendritic cells, where increased acidification results in increased antigen degradation in the lysosome and increased antigen presentation on major histocompatibility complex class II 24, 25 . To examine the effects of NCOA7 on V-ATPase-dependent lysosomal activation, we quantified the degradative activity of three different lysosomal cysteine proteases-cathepsins B, L and K-using Magic Red assays, which employ cathepsin-specific target peptide sequences coupled to a fluorophore that is activated on peptide cleavage (thought to occur primarily within endolysosomes 26 ). As shown in Fig. 3d , the degradative activity of each cathepsin was substantially increased by NCOA7 expression. To verify that NCOA7 increases the degradation of endocytosed antigen (as opposed to membrane-permeable substrates), we measured the degradation rate of boron-dipyrromethene dye-conjugated ovalbumin (DQ Ovalbumin (DQ-Ova)) by flow cytometry in NCOA7-expressing and control cells (controlling for any difference in endocytic uptake with Alexa Fluor 647-conjugated ovalbumin (Ova-647)). Fig. 3e shows that NCOA7 promotes the degradation of DQ-Ova, demonstrating that the increase in acid-dependent lysosomal protease activity enhances the degradation of material entering cells by endocytosis, further supporting the assertion that NCOA7 promotes V-ATPase activity.
Here, we identify the short isoform of human NCOA7 (isoform 4) as an IFNα -inducible inhibitor of viruses entering the cell by endocytosis. NCOA7 interacts with V-ATPase and stimulates vesicle acidification, lysosomal protease activity and the degradation of endocytosed material. These perturbations compromise the fusion capabilities of viruses that are adapted to the dynamics of the endolysosomal pathway, thereby inhibiting infection. The endocytic pathway is also important for the entry of many bacterial pathogens and toxins, and a role for OXR1/NCOA7 homologues has been suggested in protection from Vibrio cholera infection in Drosophila models 27 . These findings add innate immunity to the growing number of biological contexts for which regulation of V-ATPase is a focus of investigation: for instance, cellular nutrition, the pathology of neurodegeneration, adaptive immunity and the growth of transformed cells 24, 28, 29 . Finally, in addition to providing important insights into the antiviral action of IFN, the identification of this cytokine-responsive mechanism for regulating the endolysosomal system may facilitate therapeutic manipulation of disease processes that stem from V-ATPase-associated endolysosomal dysfunction.
Methods
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Plasmids and constructs. The EasiLV system including pEasiLV-MCS and pEasiLV-CD8-Flag (negative control) has been described, as has the lentiviral vector system employing pRRL.sin.cPPT.CMV/IRES-puro.WPRE used for the generation of cell lines stably expressing genes of interest 9 . The cytomegalovirus promoter from the pRRL.sin.cPPT.CMV/IRES-puro.WPRE system was replaced with a spleen focus-forming virus promoter (amplified from HR SIN CSGW, a gift from P. Lehner, and cloned using ClaI/BamHI) to yield pRRL. sin.cPPT.SFFV/IRES-puro.WPRE. NCOA7 variant 6 (NM_001199622.1) (encoding isoform 4 NP_001186551.1) was amplified using the SuperScript III One-Step RT-PCR System with Platinum Taq (Invitrogen) from 100 ng RNA obtained from IFNα -treated monocyte-derived macrophages using primers 5′ -aaatttggatccATGAGAGGCCAAAGATTACCCTTGG-3′ and 5′ -aaatttCTCGAGTCAATCAAATGCCCACACCTCCAG-3 (or the Flag-tagged 5 ′ -aaatttggatccATGGACTACAAAGACGACGACAAAAGAGGCCAAAGATTAC CCTTGG-3′ ). A codon-optimized version of the NCOA7 coding sequence, with the 25 first codons modified, was synthesized (Eurofins; 5′ -atgcgcggtcagcgtctgccactagatattcaaatcttttactgcgcgcgtcccgatgaggaaccgttcgtaaaa) and amplified by PCR. Firefly luciferase cDNA was amplified from pGL4 (Promega) and E2-crimson cDNA was amplified from pEasiLV-MCS. The cDNAs were inserted into BamHI-XhoI-digested pRRL.sin.cPPT.CMV/IRES-puro.WPRE, pRRL.sin.cPPT.SFFV/IRES-puro.WPRE or pEasiLV-MCS. NL4-3/Nef-IRES-GFP and NL4-3/Nef-IRES-Renilla were obtained from the National Institutes of Health (NIH) AIDS Reagent Program (pBR43IeG; catalogue number 11349) and S. Chanda, respectively. pBlaM-Vpr and pAdVAntage have been described 30 . HIV-1-, feline immunodeficiency virus-, simian immunodeficiency virusand equine infectious anaemia virus-based vector plasmids, which express GFP on infection, have previously been described 11, [31] [32] [33] [34] , as have the Env-encoding constructs phCMV-MLV-A 35 , phCMV-RD114/TR 35 and pRABIES Env 36 . To modify the A/Victoria/3/75 polymerase acidic protein gene for co-expression with NanoLuc luciferase, a polymerase acidic protein-NanoLucencoding fragment 37 , in which polymerase acidic protein is fused with the porcine teschovirus P2A and the NanoLuc luciferase gene, was inserted into the PasI site Letters NATure MICrObIOlOGy of the PolI-RT-Victoria polymerase acidic protein plasmid. The 12-plasmid system used to rescue IAV Victoria-NanoLuc reporter virus was provided by W. Barclay. The firefly luciferase gene from pHSP1-Firefly 9 was replaced by the enhanced GFP (eGFP) coding sequence to generate pHSP1-eGFP.
HCV particles were generated using the cell culture-adapted clone J6/JFH-1 (ref. 38 ). The LentiCas9-Blast and LentiGuide-Puro vectors were a gift from F. Zhang 39 (Addgene). The LentiGuide-Neo vector was generated by replacing the puromycin resistance gene in LentiGuide-Puro with the neomycin resistance gene (amplified using PCR from pcDNA3.1 + ) and using BsiWI and MluI sites. Guide RNA coding oligonucleotides were annealed and ligated into BsmBI-digested LentiGuidePuro or LentiGuide-Neo vectors, as described (Addgene). The guide RNA coding sequences used were as follows: g1-GFP 5′ -gagctggacggcgacgtaaa, g1-CTRL 5′ -agcacgtaatgtccgtggat, g2-CTRL 5′ -caatcggcgacgttttaaat, g-IFITM3 5′ -taggcctggaagatcagcac, g1-NCOA7 5′ -aaaaggctcttcgtcaggtc, g2-NCOA7 5′ -ttcacaaaaggctcttcgtc and g3-NCOA7 5′ -ggatgtccaagggtaatctt. The three NCOA7 guides were designed to target the first coding exon of NCOA7 variant 6 (NM_001199622.1), which is unique to the short IFN-inducible isoform 4 (NP_001186551.1) studied herein.
Cell lines. Human 293T, U87MG CD4
+ CXCR4 +9 , A549, Madin-Darby canine kidney (MDCK) and Huh-7.5 cells were maintained in complete Dulbecco's modified Eagle medium (DMEM) (Gibco) and THP-1 cells were maintained in Roswell Park Memorial Institute 1640 medium (Gibco), both supplemented with 10% foetal bovine serum and penicillin/streptomycin. Non-essential amino acids were added for Huh-7.5 cells. 293T, A549, MDCK and THP-1 cells were obtained from the American Type Culture Collection. Huh-7.5 cells were originally obtained from the Rice Laboratory 40 . U87MG cells were originally obtained from the NIH AIDS Reagent Program and modified to express CD4 and CXCR4 (ref. 9 ). A549, 293T, U87MG CD4 + CXCR4 + and Huh-7.5 cells stably expressing NCOA7, CD8 or E2-crimson were generated by transduction with either RRL.sin.cPPT.CMV/IRESpuro.WPRE-or RRL.sin.cPPT.SFFV/IRES-puro.WPRE-containing vectors (cDNA as indicated) and maintained under 1 μ g ml −1 puromycin selection. For CRISPR-Cas9-mediated gene disruption, A549 cells stably expressing Cas9 were first generated by transduction with the LentiCas9-Blast vector followed by blasticidin selection at 10 μ g ml . Cas9-expressing A549s were then transduced with guide RNA expressing LentiGuide-Puro and Lentiguide-Neo vectors and cells selected with antibiotics for at least 15 d. Single CRISPR-Cas9 knockout cellular clones were isolated using a FACSAria IIu cell sorter (Becton Dickinson).
When indicated, IFNα (INTRON A; Merck Sharp & Dohme) was added at 1,000 U ml −1 for 16-24 h before virus infection. Cells were treated with 50 nM bafilomycin A1 (an inhibitor of V-ATPase) (Sigma-Aldrich) for 1 h before infection and throughout the assay where indicated; cycloheximide (SigmaAldrich) was used at 1 mM to prevent de novo protein synthesis, and the media was replenished every 2 h if required. Lentiviral production and infection. Lentiviral vector stocks were obtained by polyethylenimine, TransIT-2020 (Mirus Bio) or Lipofectamine 3000 (Thermo Scientific)-mediated multiple transfection of 293T cells in six-well plates with vectors expressing Gag-Pol, the miniviral genome, the Env glycoprotein and, when required (that is, for EasiLV production), a TetR-KRAB expression plasmid 41 (pptTRKrab) at a ratio of 1:1:0.25:0.5. The culture medium was changed 6 h posttransfection, and vector-containing supernatants were harvested 36 h later, filtered and stored at − 80 °C. Wild-type HIV-1 particles (NL4-3/Nef-IRES-GFP and NL4-3/Nef-IRES-Renilla) were generated by polyethylenimine-based transfection of 293T cells. β -lactamase-Vpr (BlaM-Vpr)-carrying viruses, VSV-G-pseudotyped or bearing the wild-type Env, were produced by co-transfection of 293T cells with pMD.G (or not), the NL4-3/Nef-IRES-Renilla provirus expression vector, pBlaMVpr and pAdVAntage at a ratio of (1.33:)4:1:0.5, as previously described 30 . For the EasiLV-based experiments, U87MG CD4 + CXCR4 + cells were transduced with EasiLV stocks encoding genes of interest and the medium changed at 6 h. Doxycycline (0.4-1 μ g ml −1 ) was added for 24-48 h, and the cells were plated at 2.5 × 10 4 per well in 96-well plates, then challenged with GFP-expressing virus stocks or NL4-3. The percentage of infected, GFP-expressing cells was enumerated by flow cytometry 48 h after infection.
HIV-1 NL4-3 -containing, filtered supernatants were routinely purified by ultracentrifugation through a sucrose cushion (20% w/v; 75 min; 4 °C, 28,000 r.p.m. using a Beckman Coulter SW 32 rotor), resuspended in DMEM medium without serum and stored in small aliquots at − 80 °C. Viral particles were normalized by p24
Gag enzyme-linked immunosorbent assay or p24 Gag AlphaLisa (PerkinElmer) and/or by determining their infectious titres on U87MG cells (for GFP-expressing lentiviral vectors, retroviral vectors and HIV-1). The MOI for lentiviral vector stocks was determined by infecting a known number of cells with standardized amounts of viral particles and evaluating by flow cytometry the percentage of infected cells 2-3 d later. For instance, an MOI of 0.1 would theoretically correspond to the volume of virus necessary to obtain 10% of GFP-expressing cells.
IAV production and infection.
A/Eng/195/2009 and A/Victoria/3/75 particles were provided by W. Barclay and amplified in MDCK cells using serum-free DMEM containing 0.5 µ g ml −1 L-1-p-Tosylamino-2-phenylethyl chloromethyl ketone (TPCK)-treated trypsin (Sigma-Aldrich). Stocks were titred by plaque assays on MDCK cells, or on A549 cells to determine MOIs defined by the proportion of nucleoprotein-positive nuclei at 12 h post-infection. A 12-plasmid system was used to rescue A/Victoria/3/75 and the IAV Victoria-NanoLuc reporter virus. The 8 PolI plasmids (0.5 µ g each) and 4 rescue plasmids (PB1, PB2 and polymerase acidic protein (0.32 µ g each) and nucleoprotein (0.64 µ g)) were cotransfected into 293T cells in 6-well plates using Lipofectamine 3000 (Thermo Scientific). After 24 h, the cells were removed and co-cultured with MDCK cells in 25 ml flasks. The first 8 h of co-culture was carried out in 10% serum, after which the medium was replaced with serum-free medium containing 0.5 µ g ml
of TPCK-treated trypsin. Supernatants from day 5 post-transfection were used for virus amplification on MDCK cells.
All IAV challenges were performed in serum-free DMEM for 1 h (unless otherwise specified) and the medium was subsequently replaced with DMEM containing 10% foetal bovine serum (where the experiment lasted more than 1.5 h). For microscopy-based infectivity assays, A549 cells stably expressing CD8 or NCOA7 were plated on coverslips in 12-well plates at a density of 1 × 10 5 cells per well. The following day, cells were infected with A/Eng/195/2009 (MOI = 10). Fixation was performed at 5 h post-infection using 4% paraformaldehyde (PFA) in phosphate buffered saline (PBS) for 10 min, and the cells were permeabilized using 0.2% Triton X-100 for 10 min. After quenching and blocking in buffer NGB (50 mM NH 4 Cl, 2% goat serum and 2% bovine serum albumin in PBS) for 1 h, cells were incubated with anti-nucleoprotein antibody (Hb65; provided by Y. Yamauchi) 14 , diluted in buffer NGB for 1 h and subsequently incubated with an Alexa Fluor 488-conjugated anti-mouse secondary antibody. Cells were then stained with 1 μ g ml −1 4′ ,6-diamidino-2-phenylindole (DAPI), washed, mounted on coverslips and examined using a Nikon A1 confocal microscope (10× objective) with captured images analysed using Fiji 42 to determine the percentage of GFPexpressing cells. For time-lapse microscopy, 293T cells stably expressing CD8 or NCOA7 were seeded (5 × 10 4 per well) in a 48-well plate and transfected with 0.1 μ g pHSP1-eGFP using Lipofectamine 2000 (Thermo Scientific). pHSP1-eGFP is a minigenome-like reporter construct that expresses GFP and, when transfected into target cells, is transcribed by host RNA polymerase to produce a negative sense, viral genomic-like segment (with 5′ -triphosphate and 3′ -hydroxyl). On IAV infection, this segment is recognized by the viral RNA polymerase to generate GFP-expressing messenger RNA (mRNA). After ~24 h, the cells were infected with A/Eng/195/2009 (MOI = 1), then monitored by time-lapse microscopy with images acquired at 20-min intervals from 2 to ~18 h post-infection using a Nikon Ti-Eclipse wide-field inverted microscope (40× objective) and controlled by NIS-Elements software. Videos were created using Fiji 42 . The Victoria-NanoLuc infection experiments were performed in duplicate or triplicate in 96-well plates with cultures maintained for 7 h post-challenge. NanoLuc activity was measured with the Nano-Glo assay system (Promega), and luminescence was detected using a plate reader (Infinite 200 PRO; Tecan).
HCV production and infection. Cell culture-derived HCV particle stocks were produced by electroporation of in vitro-transcribed viral RNA into Huh-7.5 cells using a Gene Pulser Xcell (Bio-Rad) 43 . A cell culture-adapted J6/JFH-1 derivative virus named Clone 2 was used for this study. Virus-containing supernatants were collected 48, 72 and 96 h post-electroporation and titrated by limiting dilution assay, as described 44 . Transduced Huh-7.5 cells were seeded in 24-well plates, challenged with virus (MOI = 0.5) and incubated for 48 h. Cells were harvested using Accumax (eBioscience), fixed with 4% PFA, permeabilized with PBSsaponin (0.2%) and stained for 1 h at room temperature with an Alexa Fluor 647-conjugated antibody (9E10 clone) specific for the HCV non-structural protein NS5A in PBS-saponin (0.2%). The percentage of infected cells was determined by flow cytometry.
Quantification of mRNA expression. 3-5 × 10 5 cells with or without 24 h treatment with IFNα were harvested and total RNA was extracted using an RNeasy kit (Qiagen) employing on-column DNase treatment. Some 500 ng RNA was used to generate cDNA, which was analysed by quantitative PCR using TaqMan gene expression assays (Applied Biosystems) for ACTB (Hs99999903_m1) or GAPDH (Hs99999905_m1). For the short isoform of NCOA7, the primers used were 5′ -GATTACCCTTGGACATCCAGATTTTCTATT-3′ and 5′ -CACCTCTTCGTCCTCGTCTTCATAGT-3′ , and the probe sequence was 5′ -FAM-AGGCAAAGCGCAGGAAGAGCACATGC-TAMRA-3′ . Triplicate reactions were run according to the manufacturer's instructions using an ABI Prism model 7900HT sequence-detection platform, and the data were analysed using RQ software (Applied Biosystems). GAPDH and ACTB mRNA expression was used to normalize the samples.
T7 endonuclease assay.
To assess CRISPR-Cas9-mediated editing of the NCOA7 and IFITM3 loci, genomic DNA was extracted from cell populations (DNeasy; Qiagen) and an amplicon spanning the targeted genomic region was generated on 50 ng DNA by touch-down PCR using the primers 5′ -tgctggtagaaatgtcagcacaatcctttc-3′ and 5′ -aaagttcattttactctaaaatccatttttggccc-3′ , 5′ -tccctgatctcagggcgggg and 5′ -aggcccgaaaccagaaggc, respectively. Amplicons
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were then subjected to denaturation, re-annealing and T7 endonuclease (NEB) digestion.
Indirect imunofluorescence. For visualization of NCOA7 localization by confocal microscopy, U87MG CD4
+ CXCR4 + cultures were transduced with lentiviral vectors containing Flag-tagged NCOA7, as described above, and subsequently plated on coverslips treated with poly-l-lysin. Fixation, staining with anti-Flag antibody (Sigma-Aldrich F3165 or F7425, or Miltenyi 130-101-576), anti-EEA1 (BD Biosciences 610457), anti-CD63 (Santa-Cruz sc5275) and anti-Lamp1 (Sigma-Aldrich L1418), and Alexa Fluor 488-and Alex Fluor 546-conjugated anti-mouse or anti-rabbit secondary, and image acquisition were performed as in previous sections with a Zeiss LSM880 confocal microscope.
Influenza A virus uptake assay. Stably expressing E2-crimson-or NCOA7-A549 cells were seeded at 10 5 cells per well in 12-well plates. The following day, medium was removed and cells were incubated in serum-free DMEM with 3 × 10 5 and 1.5 × 10 6 plaque-forming units of A/Victoria/3/75 for 20 min at 37 °C. A heat-inactivated virus was used at the highest viral input as a negative control. Cells were then trypsinized, washed and fixed in 2% PFA. BD Perm/Wash (BD Biosciences) was used to permeabilize the cells, and they were stained with antinucleoprotein antibody (Hb65) and Alexa Fluor 488 secondary antibody according to the manufacturer's instructions. Cells were analysed using a NovoCyte (Ozyme) cytometer.
Haemagglutinin acidification assay. A549 cells, parental or stably expressing CD8 or NCOA7, were seeded in six-well plates. Unmodified cells were treated with 50 nM bafilomycin A1 for 1 h before infection (inhibition control). Medium was removed and cells were infected in serum-free DMEM with A/Victoria/3/75 at an MOI of 30 and incubated for 1 h at 37 °C. Cells were then trypsinized, and both fixed and stained using IntraStain (Dako) with monoclonal antibody A1 (ref.
14 ), which is specific for haemagglutinin that has undergone low pH-induced conformational change (provided by Y. Yamauchi). Alexa Fluor 647-conjugated anti-mouse total immunoglobulin G (Life Technologies) was used as a secondary antibody, and cells were analysed by imaging flow cytometry (see below) using the 647 nm laser for excitation.
Membrane fusion assay.
A/Victoria/3/75 was labelled with the self-quenching dye SP-DiOC18(3) (Molecular Probes). SP-DiOC18(3) was added to 1 ml of virus stock in serum-free DMEM (containing approximately 2.5 × 10 7 infectious units per ml) at a final concentration of 0.2 μ M in a screw-capped Eppendorf tube 45 . The tube was protected from light, incubated while rolling for 1 h at room temperature and subsequently stored at − 80 °C or used as required. For the heat-inactivation control, virus was kept at 75 °C for 30 min and returned to room temperature before labelling. Labelled virus preparations were passed through a 0.45 μ m filter. Labelled virus was diluted in serum-free DMEM for infection of CD8-or NCOA7-expressing A549 monolayers at an MOI of 10. Cells were incubated for 1.5 h after infection, harvested with trypsin, fixed with 4% PFA for 10 min and analysed by imaging flow cytometry using the 488 nm laser for excitation.
BlaM-Vpr assay for lentiviral entry. The BlaM-Vpr assay has previously been described 30 . Briefly, 2 × 10 5 E2-crimson-or NCOA7-expressing U87MG CD4 + CXCR4 + cells were plated in 24-well plates the day before infection. Cells were mock infected or incubated with increasing amounts of VSV-G-pseudotyped, or wild-type Env-carrying, BlaM-Vpr-containing NL4-3/Nef-IRES-Renilla viruses (31.2, 62.5 or 125 ng p24) for 3 h. Cells were then washed once in CO 2 -independent media and loaded with CCF2-AM substrate (Invitrogen) containing development media (CO 2 -independent media containing 1.6 mM probenecid) for 2 h at room temperature before 2 washes and incubation at room temperature for 16 h in development media. Finally, cells were harvested, washed and fixed in 2% PFA, before analysis using a FACSCanto II (BD Biosciences).
vRNP import assay. A549 cells were plated and unmodified cells treated with bafilomycin A1 as above. Cycloheximide (1 mM) was maintained in the medium throughout the experiment. Cells were infected with A/Eng/195/2009 at an MOI of 10. The medium was changed at 1 h (as above) and again at 3 h to ensure optimal cycloheximide activity. Cells were fixed in 4% PFA at 5 h, then stained with anti-nucleoprotein (Hb65) antibody and secondary antibody, as above, using Perm/Wash (BD Biosciences) according to the manufacturer's instructions. DAPI staining was used to demarcate the nucleus (0.1 μ g ml −1 for 5 min). Cells were analysed by imaging flow cytometry using a 642 nm laser for excitation. For the parallel visualization of nuclear vRNP import by confocal microscopy, cells were plated on coverslips as described above. Infection conditions were identical, and staining and image acquisition were performed as described.
Vesicle acidification and cathepsin activity assays. Transduced A549 cells were plated in 6-well plates and treated with 0.1 μ M LysoSensor Green DND-189 (Molecular Probes) for 1 h, or with 10 μ M LysoSensor Yellow/Blue DND-160 for 30 min at 37 °C. Cells were subsequently trypsinized, washed and resuspended for immediate analysis by imaging flow cytometry. A 488 nm laser was used for LysoSensor Green. For LysoSensor Yellow/Blue, a 405 nm laser was used for excitation and the ratio of the mean fluorescence intensity of the cells in channels 420-505 nm and 505-570 nm was measured for the analysis. For analysis by confocal microscopy, A549 cells were plated in glass-bottomed dishes and, the following day, treated with 1 μ M LysoSensor Green for 1 h. Living cells were subsequently washed and visualized using a Nikon A1R confocal microscope and 488 nm laser. To analyse cathepsin B, L and K activity, the Magic Red reagents (ImmunoChemistry Technologies) specific for each of these proteases were reconstituted in DMSO and subsequently diluted in distilled H 2 O to form a 26× solution as per the manufacturer's instructions. Approximately 5 × 10 5 transduced A549 cells were trypsinized from a 6-well plate and resuspended in 150 μ l medium, to which the reagent was added. Cells were incubated for 1.5 h at 37 °C, washed, fixed in 2% PFA and analysed by imaging flow cytometry using a 561 nm laser for excitation.
Ovalbumin degradation assay. CD8-or NCOA7-expressing cells were plated in 48-well plates. Cells were incubated in serum-free media containing 250 μ g ml
of DQ-Ova, which emits fluorescence on degradation, or Ova-647 for 1 h at 37 °C followed by washing. Ova-647-containing cells were subsequently fixed, whereas DQ-Ova-containing samples were incubated for a further 4 h at 37 °C before washing and fixation. DQ-Ova and Ova-647 fluorescence were enumerated by flow cytometry. DQ-Ova fluorescence at 4 h was normalized by Ova-647 at 1 h to allow for any differences in uptake of the reagent.
Imaging flow cytometry and flow cytometry. Cells were processed using an Amnis ImageStreamX at 60× magnification with the indicated excitation laser, in addition to the brightfield system, according to the manufacturer's instructions. Amnis IDEAS software was used to analyse the data. The IDEAS automated spot-counting wizard, performed on the CD8-expressing population, was used to determine the optimal spot-counting algorithm for individual experiments. For the nuclear vRNP import assay, spot counting was performed on the 'mask' (region of interest) demarcated by DAPI staining using a threshold of 40% of the maximum DAPI staining intensity. Standard flow cytometry was performed using the FACSCanto II (BD Biosciences) or the NovoCyte (Ozyme).
Co-immunoprecipitation and immunoblot analysis. U87MG cells were stably transduced with vectors carrying RRL.sin.cPPT.CMV/Flag-NCOA7.WPRE or RRL.sin.cPPT.CMV/Flag-E2-crimson-.WPRE and selected with 1 μ g ml
puromycin. Some 15-22 × 10 6 cells were washed twice in cold PBS and resuspended in lysis buffer (20 mM Hepes-NaOH pH 7.5, 150 mM NaCl, 1% NP-40 and protease inhibitor cocktail). The lysates were clarified by centrifugation at 1,000g, for 10 min at 4 °C and then incubated with Flag-magnetic beads (Life Technologies) for 3 h at 4 °C. The beads were washed 5 times and the immunoprecipitated proteins eluted using 3× Flag peptide (150 μ g ml ; Sigma-Aldrich) for 1.5-2 h. Cell lysates and immunoprecipitation eluates were supplemented with sample buffer (50 mM Tris-HCl pH 6.8, 2% sodium dodecyl sulfate, 5% glycerol, 100 mM dithiothreitol and 0.02% bromphenol blue), resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis and analysed by immunoblotting using primary antibodies specific for the Flag epitope (Sigma-Aldrich F3165), tubulin (mouse monoclonal DM1A; Sigma-Aldrich T9026), ATP6V1B2 (Proteintech 15097-1-AP), ATP6V1A (Proteintech 17115-1-AP), ATP6V1E1 (Abcam Ab111733) and ATP6V1G2 (Proteintech 25316-1-AP), followed by secondary horseradish peroxidase-conjugated anti-mouse or anti-rabbit immunoglobulin antibodies and chemiluminescence Clarity or Clarity Max substrate (Bio-Rad). A Bio-Rad ChemiDoc imager was used.
Statistical analysis. Statistical significance was determined by two-tailed MannWhitney U-test in Fig. 1g and Supplementary Fig. 2d .
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
The datasets generated and/or analysed during the current study are available from the corresponding authors on reasonable request. 
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted FlowJo v10 was used to analyze flow cytometry data. ImageJ64 was used to analyse microscopy. Amnis IDEAs was used to analyse imaging flow cytometry.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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Flow Cytometry Plots
Confirm that:
The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology Sample preparation
Cell cultures were treated as indicated and harvested by trypsinization. Afterwards, cells were fixed with 2% formaldehyde for 20 minutes and and washed in 1x PBS.
Instrument
Flow cytometry was performed using a BD Biosciences FACS Canto II Flow Cytometry System.
Software
All data was analyzed using the FlowJo software.
Cell population abundance Approx 3000 cells per condition were used.
Gating strategy
Using the FSC/SSC gating, debris was removed by gating on the main cell population. GFP or E2 crimson positive cells were defined on the basis of uninfected or untransduced cells.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
